Infigratinib | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Infigratinib
Health Canada Patents

Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Contact Supplier

IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

Contact Supplier

IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

Contact Supplier

medac CDMO: Tailored CDMO services for injectables in syringes, cartridges & vials – aseptic, reliable, flexible and a solution ahead.

Contact Supplier

Coral

Contact Supplier

ICE Pharma offers a unique range of bile acid products and best-in-class services for the pharmaceutical industry.

Contact Supplier

Infigratinib

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 NDC API

1 API Suppliers
1 NDC API

DEVELOPMENTS

39 Drugs in Development

39 Drugs in Development

INTERMEDIATES

7 Intermediate Suppliers

7 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 2 FDA Orange Book

2 FDF Dossiers
2 FDA Orange Book

DIGITAL CONTENT

15 News #PharmaBuzz

15 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

1 US Medicaid Prescriptions

PATENTS & EXCLUSIVITIES

8 US Patents, 4 US Exclusivities, 8 Health Canada Patents

8 US Patents
4 US Exclusivities
8 Health Canada Patents

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

8 All

01 8Bereskin & Parr LLP

filter Patent Reset all filters

8 All

01 42570873

02 42781431

filter Product Reset all filters

8 All

01 8INFIGRATINIB

filter Dosage Reset all filters

8 All

01 8CAPSULE

filter Exp Date Reset all filters

8 All

01 42025-06-23

02 42030-12-06

Product Main Page

01

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2570873

Filing Date : 2005-06-23

Strength per Unit : 50 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2781431

Filing Date : 2010-12-06

Strength per Unit : 50 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2570873

Filing Date : 2005-06-23

Strength per Unit : 75 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2781431

Filing Date : 2010-12-06

Strength per Unit : 75 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2570873

Filing Date : 2005-06-23

Strength per Unit : 100 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2781431

Filing Date : 2010-12-06

Strength per Unit : 100 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

07

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2570873

Filing Date : 2005-06-23

Strength per Unit : 125 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2025-06-23

Date Granted : 2014-04-29

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

08

Bereskin & Parr LLP

INFIGRATINIB

Formnext Forum

Not Confirmed

Bereskin & Parr LLP

Country

Formnext Forum

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

INFIGRATINIB

Brand Name : TRUSELTIQ

Patent Number : 2781431

Filing Date : 2010-12-06

Strength per Unit : 125 mg / dose

Dosage Form : CAPSULE

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2030-12-06

Date Granted : 2017-10-31

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!